Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

423
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
423
Aortic Regurgitation III: Medical Management01:25

Aortic Regurgitation III: Medical Management

540
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
540
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

1.2K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Perspective Directions in Management of Severe Group Two Pulmonary Hypertension].

Kardiologiia·2017
Same author

[Experience of Treatment of Spontaneous Rupture of Left Ventricular Posterior Wall After Mitral Valve Replacement].

Kardiologiia·2017
Same author

[Aortic valve replacement with stentless bioprosthesis: surgical technique and early outcomes].

Khirurgiia·2016
Same author

[The mithral valve replacement with biological prostheses: early and long-term results].

Khirurgiia·2013
Same author

[A case of severe intravascular hemolysis after double mechanical heart valve implantation].

Kardiologiia·2013
Same author

[The study of microcirculation in walls of chambers of the heart in patients with aortic stenosis in dependence on heart failure stage].

Kardiologiia·2011

Related Experiment Video

Updated: Mar 19, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

12.0K

[Aortic valve replacement with stentless bioprosthesis].

D A Astapov1, D P Demidov1, E I Semenova1

  • 1Academician E.N. Meshalkin Research Institute of Circulation Pathology, Ministry of Health of the Russian Federation, Novosibirsk, Russia.

Khirurgiia
|June 9, 2016
PubMed
Summary

The BioLAB Mono stentless bioprosthesis shows excellent early hemodynamic performance in aortic valve replacement. This aortic bioprosthesis implantation is easy and reproducible, with no valve dysfunction observed.

More Related Videos

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.5K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.9K

Related Experiment Videos

Last Updated: Mar 19, 2026

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

12.0K
Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model
05:31

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

3.5K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.9K

Area of Science:

  • Cardiovascular Surgery
  • Biomedical Engineering
  • Prosthetic Heart Valves

Context:

  • Severe aortic stenosis necessitates aortic valve replacement.
  • Stentless bioprostheses offer potential hemodynamic advantages.
  • Evaluating novel prosthetic devices is crucial for clinical practice.

Purpose:

  • To prospectively assess the hemodynamic performance of the BioLAB Mono stentless bioprosthesis in the aortic position.
  • To evaluate the ease and reproducibility of BioLAB Mono implantation.

Summary:

  • Twenty-seven patients with severe aortic stenosis underwent aortic valve replacement with the BioLAB Mono stentless bioprosthesis.
  • The mean aortic cross-clamping time was 81 minutes.
  • Early postoperative echocardiography revealed a mean peak pressure gradient of 18 mmHg, with no instances of valve dysfunction.

Impact:

  • The BioLAB Mono stentless bioprosthesis demonstrates excellent early hemodynamic performance.
  • The implantation procedure is characterized by ease and reproducibility.
  • Findings support the clinical utility of the BioLAB Mono bioprosthesis for aortic valve replacement.